Tiziana Life Sciences strengthens intranasal foralumab development with Renaissance Lakewood partnership
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a clinical-stage biotechnology company focused on immunomodulation therapies, has announced a strategic partnership with Renaissance Lakewood LLC, a leading ... Read More
Takeda announces positive results for mezagitamab in Phase 2 ITP study
Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of mezagitamab ... Read More
WuXi Biologics and Toregem BioPharma to advance tooth regeneration treatment
WuXi Biologics ("WuXi Bio"), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a strategic partnership with Toregem BioPharma, a biotech startup ... Read More
Roche’s Tecentriq secures FDA approval for small cell lung cancer treatment
Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of Tecentriq (atezolizumab). This new approval marks a ... Read More
X4 Pharmaceuticals completes merger with Arsanis to advance rare disease and cancer treatments
X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases and cancer. This strategic move unites two ... Read More